256 related articles for article (PubMed ID: 35286385)
1. HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.
Li L; Kim JH; Lu W; Williams DM; Kim J; Cope L; Rampal RK; Koche RP; Xian L; Luo LZ; Vasiljevic M; Matson DR; Zhao ZJ; Rogers O; Stubbs MC; Reddy K; Romero AR; Psaila B; Spivak JL; Moliterno AR; Resar LMS
Blood; 2022 May; 139(18):2797-2815. PubMed ID: 35286385
[TBL] [Abstract][Full Text] [Related]
2. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
3. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
4. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
Rampal R; Ahn J; Abdel-Wahab O; Nahas M; Wang K; Lipson D; Otto GA; Yelensky R; Hricik T; McKenney AS; Chiosis G; Chung YR; Pandey S; van den Brink MR; Armstrong SA; Dogan A; Intlekofer A; Manshouri T; Park CY; Verstovsek S; Rapaport F; Stephens PJ; Miller VA; Levine RL
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5401-10. PubMed ID: 25516983
[TBL] [Abstract][Full Text] [Related]
5. HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation.
Chia L; Wang B; Kim JH; Luo LZ; Shuai S; Herrera I; Chen SY; Li L; Xian L; Huso T; Heydarian M; Reddy K; Sung WJ; Ishiyama S; Guo G; Jaffee E; Zheng L; Cope LM; Gabrielson K; Wood L; Resar L
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36919699
[TBL] [Abstract][Full Text] [Related]
6. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.
Yang Y; Akada H; Nath D; Hutchison RE; Mohi G
Blood; 2016 Jun; 127(26):3410-23. PubMed ID: 27081096
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
[TBL] [Abstract][Full Text] [Related]
8. HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks.
Shah SN; Kerr C; Cope L; Zambidis E; Liu C; Hillion J; Belton A; Huso DL; Resar LM
PLoS One; 2012; 7(11):e48533. PubMed ID: 23166588
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy.
Brkic S; Stivala S; Santopolo A; Szybinski J; Jungius S; Passweg JR; Tsakiris D; Dirnhofer S; Hutter G; Leonards K; Lischer HEL; Dettmer MS; Neel BG; Levine RL; Meyer SC
Leukemia; 2021 Oct; 35(10):2875-2884. PubMed ID: 34480104
[TBL] [Abstract][Full Text] [Related]
10. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
11. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
12. Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms.
Gou P; Liu D; Ganesan S; Lauret E; Maslah N; Parietti V; Zhang W; Meignin V; Kiladjian JJ; Cassinat B; Giraudier S
Blood Cancer J; 2024 Jan; 14(1):1. PubMed ID: 38177095
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
Front Immunol; 2020; 11():604142. PubMed ID: 33329600
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm.
Rahman MF; Yang Y; Le BT; Dutta A; Posyniak J; Faughnan P; Sayem MA; Aguilera NS; Mohi G
Nat Commun; 2022 Sep; 13(1):5347. PubMed ID: 36100596
[TBL] [Abstract][Full Text] [Related]
15. Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
Schnöder TM; Eberhardt J; Koehler M; Bierhoff HB; Weinert S; Pandey AD; Nimmagadda SC; Wolleschak D; Jöhrens K; Fischer T; Heidel FH
J Cancer Res Clin Oncol; 2017 May; 143(5):807-820. PubMed ID: 28233092
[TBL] [Abstract][Full Text] [Related]
16. High-mobility-group protein A1 in MPN progression.
Schwaller J
Blood; 2022 May; 139(18):2730-2732. PubMed ID: 35511192
[No Abstract] [Full Text] [Related]
17. Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice.
Akada H; Akada S; Hutchison RE; Mohi G
Leukemia; 2014 Aug; 28(8):1627-35. PubMed ID: 24480985
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
[No Abstract] [Full Text] [Related]
19. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
[TBL] [Abstract][Full Text] [Related]
20. HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis.
Schuldenfrei A; Belton A; Kowalski J; Talbot CC; Di Cello F; Poh W; Tsai HL; Shah SN; Huso TH; Huso DL; Resar LM
BMC Genomics; 2011 Nov; 12():549. PubMed ID: 22053823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
